The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease
Long-acting muscarinic antagonists (LAMAs) play a central role in the management of chronic obstructive pulmonary disease (COPD). Previously, only one LAMA (tiotropium) was available for the treatment of COPD, necessitating the development of other therapeutic options due to the heterogeneity of COP...
Main Authors: | François Maltais, Julie Milot |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2012-12-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/1753465812463626 |
Similar Items
-
Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease
by: Sims MW, et al.
Published: (2011-09-01) -
Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
by: Jones PW
Published: (2015-03-01) -
EVALUATION OF EFFECTIVENESS OF ACLIDINIUM BROMIDE FOR PATIENTS WITH OCCUPATIONAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
by: NV V Vakurova, et al.
Published: (2017-06-01) -
Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
by: Matera MG, et al.
Published: (2016-01-01) -
A Real-World Observational Study Examining the Impact of Aclidinium Bromide Therapy on the Quality of Life, Symptoms, and Activity Impairment of Patients with Chronic Obstructive Pulmonary Disease: The Greek ON-AIR Study
by: Kostikas K, et al.
Published: (2020-03-01)